E Fund Management Co. Ltd. Makes New Investment in Twist Bioscience Corporation $TWST

E Fund Management Co. Ltd. purchased a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 5,744 shares of the company’s stock, valued at approximately $591,000.

A number of other institutional investors have also modified their holdings of TWST. Meeder Asset Management Inc. acquired a new position in Twist Bioscience during the 2nd quarter worth about $162,000. BlackRock Inc. acquired a new position in Twist Bioscience in the 2nd quarter valued at about $600,191,000. Deutsche Bank AG acquired a new position in Twist Bioscience in the 2nd quarter valued at about $9,265,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Twist Bioscience during the second quarter worth about $2,828,000. Finally, Bank of New York Mellon Corp purchased a new stake in Twist Bioscience during the second quarter worth about $19,722,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TWST. Robert W. Baird upped their price target on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Barclays lifted their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Guggenheim boosted their price objective on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Canaccord Genuity Group upped their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, UBS Group set a $89.00 target price on shares of Twist Bioscience in a report on Monday, June 15th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.30.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $136.33 on Friday. The company has a market cap of $8.55 billion, a P/E ratio of -61.41 and a beta of 2.14. The firm has a fifty day moving average price of $99.30 and a 200 day moving average price of $69.80. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $145.51.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.33 earnings per share. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Paula Green sold 291 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president owned 120,414 shares in the company, valued at $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 113,318 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the transaction, the chief executive officer directly owned 818,938 shares of the company’s stock, valued at $102,498,280.08. This trade represents a 12.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 151,529 shares of company stock worth $17,708,772. Insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.